RACK1 and gastrointestinal stromal tumor: Figure 2I shows that imatinib treatment strongly inhibited tumor growth in GIST-882-con and GIST-882R/shRACK1 tumors (p < 0.05), suggesting that mice receiving implantations of GIST-882-RACK1 and GIST-882R-con were more resistant to imatinib than those receiving GIST-882-con and GIST-882R/shRACK1, respectively.